Leerink Partnrs Forecasts Weaker Earnings for Beta Bionics

Key Points

• Leerink Partners has lowered its Q3 2025 EPS estimate for Beta Bionics from ($0.42) to ($0.43), while forecasting additional losses for future quarters.
• Beta Bionics reported a quarterly EPS of ($0.39), which surpassed the consensus estimate of ($0.51), along with revenue of $23.24 million, exceeding the $19.73 million estimate.
• Multiple brokerages have recently provided varying ratings and price targets for Beta Bionics, with a consensus price target of $22.56 and an average rating of "Moderate Buy."

Beta Bionics, Inc. (NASDAQ:BBNX - Free Report) - Leerink Partnrs decreased their Q3 2025 earnings per share estimates for Beta Bionics in a report released on Tuesday, July 29th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of ($0.43) for the quarter, down from their previous estimate of ($0.42). Leerink Partnrs also issued estimates for Beta Bionics' Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.60) EPS, FY2026 earnings at ($2.03) EPS, FY2027 earnings at ($2.35) EPS, FY2028 earnings at ($1.38) EPS and FY2029 earnings at ($0.90) EPS.

Other equities analysts also recently issued reports about the company. The Goldman Sachs Group assumed coverage on Beta Bionics in a research report on Friday, May 30th. They issued a "neutral" rating and a $16.00 target price for the company. Robert W. Baird set a $17.00 price objective on Beta Bionics and gave the stock a "neutral" rating in a research report on Wednesday, July 30th. Wolfe Research assumed coverage on Beta Bionics in a research report on Friday, May 30th. They set an "outperform" rating and a $20.00 price objective for the company. Truist Financial raised their price objective on Beta Bionics from $18.00 to $21.00 and gave the stock a "buy" rating in a research report on Wednesday, July 30th. Finally, Lake Street Capital assumed coverage on Beta Bionics in a research report on Thursday, June 12th. They set a "buy" rating and a $30.00 price objective for the company. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Beta Bionics presently has a consensus rating of "Moderate Buy" and a consensus target price of $22.56.

Beta Bionics Trading Down 2.9%

Beta Bionics stock traded down $0.48 during trading hours on Friday, hitting $15.94. The stock had a trading volume of 321,662 shares, compared to its average volume of 512,258. Beta Bionics has a one year low of $8.89 and a one year high of $24.50. The business has a 50 day moving average of $15.79.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.12. The firm had revenue of $23.24 million during the quarter, compared to the consensus estimate of $19.73 million.

Insider Buying and Selling

In other Beta Bionics news, CFO Stephen Feider sold 1,497 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $26,781.33. Following the completion of the sale, the chief financial officer owned 45,503 shares of the company's stock, valued at approximately $814,048.67. This trade represents a 3.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 4,519 shares of company stock worth $80,845 over the last ninety days.

Institutional Investors Weigh In On Beta Bionics

A number of hedge funds have recently added to or reduced their stakes in BBNX. Strs Ohio acquired a new stake in Beta Bionics in the first quarter valued at approximately $29,000. CWM LLC acquired a new stake in Beta Bionics in the second quarter valued at approximately $58,000. Corebridge Financial Inc. acquired a new stake in Beta Bionics in the first quarter valued at approximately $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Beta Bionics during the first quarter valued at approximately $95,000. Finally, MetLife Investment Management LLC purchased a new position in shares of Beta Bionics during the first quarter valued at approximately $102,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.